These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related]
27. Consultation corner. Prostate cancer vaccine offers new direction. Drake C Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753 [No Abstract] [Full Text] [Related]
29. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process. Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED; Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252 [TBL] [Abstract][Full Text] [Related]
30. Immune-boosting prostate cancer vaccine endorsed by FDA advisors. McBride D ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780 [No Abstract] [Full Text] [Related]
37. [Immunotherapy for the treatment of prostate cancer-a comeback?]. De Santis M Urologe A; 2018 Nov; 57(11):1342-1345. PubMed ID: 30341689 [TBL] [Abstract][Full Text] [Related]
38. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
39. Cancer vaccine approval could open floodgates. Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296 [No Abstract] [Full Text] [Related]